INTELLIA THERAPEUTICS, INC. Net Income
INTELLIA THERAPEUTICS, INC. (NTLA) reported Net Income of -$106.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$106.63M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$96.23M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$95.79M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$101.32M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2020 was -$134.23M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2019 was -$474.19M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2018 was -$85.34M.
- INTELLIA THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2017 was -$67.54M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 8 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$106.63M 10-Q · filed 2026-08-06 | -$202.87M 10-Q · filed 2026-08-06 | -$298.65M derived: sum of 3 quarters · filed 2026-08-06 | -$399.98M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$96.23M 10-Q · filed 2026-08-06 | -$192.02M derived: sum of 2 quarters · filed 2026-08-06 | -$293.34M derived: sum of 3 quarters · filed 2026-08-06 | -$394.60M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$95.79M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$197.11M derived: sum of 2 quarters · filed 2026-04-30 | -$298.37M derived: sum of 3 quarters · filed 2026-08-06 | -$412.69M DEF 14A · filed 2026-04-30 | ||
| 2025-09-30 | -$101.32M 10-Q · filed 2025-11-06 | -$202.58M derived: sum of 2 quarters · filed 2026-08-06 | -$316.91M 10-Q · filed 2025-11-06 | -$445.81M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$101.25M 10-Q · filed 2026-08-06 | -$215.58M 10-Q · filed 2026-08-06 | -$344.48M derived: sum of 3 quarters · filed 2026-08-06 | -$480.19M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$114.33M 10-Q · filed 2026-08-06 | -$243.23M derived: sum of 2 quarters · filed 2026-08-06 | -$378.94M derived: sum of 3 quarters · filed 2026-08-06 | -$525.91M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2024-12-31 | -$128.90M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$264.61M derived: sum of 2 quarters · filed 2026-04-30 | -$411.58M derived: sum of 3 quarters · filed 2026-04-30 | -$519.02M DEF 14A · filed 2026-04-30 | ||
| 2024-09-30 | -$135.71M 10-Q · filed 2025-11-06 | -$282.69M derived: sum of 2 quarters · filed 2025-11-06 | -$390.12M 10-Q · filed 2025-11-06 | -$522.28M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-06-30 | -$146.97M 10-Q · filed 2025-11-06 | -$254.41M 10-Q · filed 2025-08-07 | -$386.57M derived: sum of 3 quarters · filed 2026-04-30 | -$508.80M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-03-31 | -$107.44M 10-Q · filed 2025-11-06 | -$239.60M derived: sum of 2 quarters · filed 2026-04-30 | -$361.82M derived: sum of 3 quarters · filed 2026-04-30 | -$485.50M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2023-12-31 | -$132.16M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$254.38M derived: sum of 2 quarters · filed 2026-04-30 | -$378.07M derived: sum of 3 quarters · filed 2026-04-30 | -$481.19M DEF 14A · filed 2026-04-30 | ||
| 2023-09-30 | -$122.22M 10-Q · filed 2024-11-07 | -$245.91M derived: sum of 2 quarters · filed 2024-11-07 | -$349.03M 10-Q · filed 2024-11-07 | -$462.44M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2023-06-30 | -$123.68M 10-Q · filed 2024-11-07 | -$226.81M 10-Q · filed 2024-08-08 | -$340.21M derived: sum of 3 quarters · filed 2026-04-30 | -$453.44M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2023-03-31 | -$103.13M 10-Q · filed 2024-11-07 | -$216.53M derived: sum of 2 quarters · filed 2026-04-30 | -$329.76M derived: sum of 3 quarters · filed 2026-04-30 | -$430.44M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2022-12-31 | -$113.41M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$226.64M derived: sum of 2 quarters · filed 2026-04-30 | -$327.31M derived: sum of 3 quarters · filed 2026-04-30 | -$474.19M DEF 14A · filed 2026-04-30 | ||
| 2022-09-30 | -$113.23M 10-Q · filed 2023-11-09 | -$213.91M derived: sum of 2 quarters · filed 2023-11-09 | -$360.78M 10-Q · filed 2023-11-09 | -$442.02M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2022-06-30 | -$100.68M 10-Q · filed 2023-11-09 | -$247.55M 10-Q · filed 2023-08-03 | -$328.79M derived: sum of 3 quarters · filed 2026-04-30 | -$400.43M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2022-03-31 | -$146.87M 10-Q · filed 2023-11-09 | -$228.11M derived: sum of 2 quarters · filed 2026-04-30 | -$299.75M derived: sum of 3 quarters · filed 2026-04-30 | -$368.56M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2021-12-31 | -$81.24M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$152.88M derived: sum of 2 quarters · filed 2026-04-30 | -$221.69M derived: sum of 3 quarters · filed 2026-04-30 | -$267.89M DEF 14A · filed 2026-04-30 | ||
| 2021-09-30 | -$71.64M 10-Q · filed 2022-11-03 | -$140.45M derived: sum of 2 quarters · filed 2022-11-03 | -$186.66M 10-Q · filed 2022-11-03 | -$228.85M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-06-30 | -$68.81M 10-Q · filed 2022-11-03 | -$115.01M 10-Q · filed 2022-08-04 | -$157.20M derived: sum of 3 quarters · filed 2022-11-03 | -$185.04M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2021-03-31 | -$46.20M 10-Q · filed 2022-11-03 | -$88.40M derived: sum of 2 quarters · filed 2022-11-03 | -$116.24M derived: sum of 3 quarters · filed 2022-11-03 | -$148.63M derived: sum of 4 quarters · filed 2022-11-03 | ||
| 2020-12-31 | -$42.19M 10-K · filed 2021-02-26 | -$70.03M derived: sum of 2 quarters · filed 2021-11-04 | -$102.42M derived: sum of 3 quarters · filed 2021-11-04 | -$134.23M 10-K · filed 2023-02-23 | ||
| 2020-09-30 | -$27.84M 10-Q · filed 2021-11-04 | -$60.23M derived: sum of 2 quarters · filed 2021-11-04 | -$92.04M 10-Q · filed 2021-11-04 | -$120.31M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | -$32.39M 10-Q · filed 2021-11-04 | -$64.20M 10-Q · filed 2021-08-05 | -$92.47M derived: sum of 3 quarters · filed 2021-11-04 | -$116.11M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-03-31 | -$31.81M 10-Q · filed 2021-11-04 | -$60.08M derived: sum of 2 quarters · filed 2021-11-04 | -$83.72M derived: sum of 3 quarters · filed 2021-11-04 | -$109.40M derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2019-12-31 | -$28.28M 10-K · filed 2021-02-26 | -$51.91M derived: sum of 2 quarters · filed 2021-02-26 | -$77.59M derived: sum of 3 quarters · filed 2021-02-26 | -$474.19M 10-K · filed 2023-02-23 | -$99.53M 10-K · filed 2020-02-27 | |
| 2019-09-30 | -$23.63M 10-K · filed 2021-02-26 | -$49.32M derived: sum of 2 quarters · filed 2021-02-26 | -$71.26M 10-Q · filed 2020-11-05 | -$90.32M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | -$25.68M 10-K · filed 2021-02-26 | -$47.62M 10-Q · filed 2020-08-06 | -$66.69M derived: sum of 3 quarters · filed 2021-02-26 | -$89.39M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | -$21.94M 10-K · filed 2021-02-26 | -$41.01M derived: sum of 2 quarters · filed 2021-02-26 | -$63.71M derived: sum of 3 quarters · filed 2021-02-26 | -$85.93M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2018-12-31 | -$19.07M 10-K · filed 2020-02-27 | -$41.77M derived: sum of 2 quarters · filed 2020-02-27 | -$63.99M derived: sum of 3 quarters · filed 2020-02-27 | -$85.34M 10-K · filed 2021-02-26 | ||
| 2018-09-30 | -$22.70M 10-K · filed 2020-02-27 | -$44.92M derived: sum of 2 quarters · filed 2020-02-27 | -$66.28M 10-Q · filed 2019-10-31 | -$90.24M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-06-30 | -$22.22M 10-K · filed 2020-02-27 | -$43.58M 10-Q · filed 2019-08-01 | -$67.54M derived: sum of 3 quarters · filed 2020-02-27 | -$82.89M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-03-31 | -$21.36M 10-K · filed 2020-02-27 | -$45.32M derived: sum of 2 quarters · filed 2020-02-27 | -$60.67M derived: sum of 3 quarters · filed 2020-02-27 | -$76.27M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2017-12-31 | -$23.96M 10-K · filed 2019-02-27 | -$39.32M derived: sum of 2 quarters · filed 2019-02-27 | -$54.91M derived: sum of 3 quarters · filed 2019-02-27 | -$67.54M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | -$15.36M 10-K · filed 2019-02-27 | -$30.95M derived: sum of 2 quarters · filed 2019-02-27 | -$43.58M 10-Q · filed 2018-10-31 | -$54.14M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | -$15.59M 10-K · filed 2019-02-27 | -$28.22M 10-Q · filed 2018-08-01 | -$38.79M derived: sum of 3 quarters · filed 2019-02-27 | -$46.27M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | -$12.63M 10-K · filed 2019-02-27 | -$23.19M derived: sum of 2 quarters · filed 2019-02-27 | -$30.68M derived: sum of 3 quarters · filed 2019-02-27 | -$37.58M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | -$10.56M 10-K · filed 2018-03-14 | -$18.05M derived: sum of 2 quarters · filed 2018-03-14 | -$24.95M derived: sum of 3 quarters · filed 2018-03-14 | -$31.63M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | -$7.48M 10-K · filed 2018-03-14 | -$14.38M derived: sum of 2 quarters · filed 2018-03-14 | -$21.07M 10-Q · filed 2017-10-31 | -$26.32M derived: sum of 4 quarters · filed 2018-03-14 | ||
| 2016-06-30 | -$6.90M 10-K · filed 2018-03-14 | -$13.59M 10-Q · filed 2017-08-01 | -$18.83M derived: sum of 3 quarters · filed 2018-03-14 | -$21.85M derived: sum of 4 quarters · filed 2018-03-14 | ||
| 2016-03-31 | -$6.69M 10-K · filed 2018-03-14 | -$11.93M derived: sum of 2 quarters · filed 2018-03-14 | -$14.95M derived: sum of 3 quarters · filed 2018-03-14 | -$17.99M derived: sum of 4 quarters · filed 2018-03-14 | ||
| 2015-12-31 | -$5.25M 10-K · filed 2017-03-14 | -$8.26M derived: sum of 2 quarters · filed 2017-03-14 | -$11.30M derived: sum of 3 quarters · filed 2017-03-14 | -$12.40M 10-K · filed 2018-03-14 | ||
| 2015-09-30 | -$3.02M 10-K · filed 2017-03-14 | -$6.06M derived: sum of 2 quarters · filed 2017-03-14 | -$7.15M 10-Q · filed 2016-11-01 | |||
| 2015-06-30 | -$3.04M 10-K · filed 2017-03-14 | -$4.13M 10-Q · filed 2016-08-04 | ||||
| 2015-03-31 | -$1.09M 10-K · filed 2017-03-14 | |||||
| 2014-12-31 | -$9.54M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |